The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain
暂无分享,去创建一个
Pierre Boulanger | P. Coric | S. DaFonseca | S. Bouaziz | B. Gay | P. Boulanger | Saw-See Hong | Bernard Gay | Serge Bouaziz | Sandrina DaFonseca | Pascale Coric | Saw See Hong
[1] F. Boisvert,et al. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation , 1995, Journal of virology.
[2] K. Lee,et al. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. , 1996, Journal of medicinal chemistry.
[3] E. Freed,et al. Human immunodeficiency virus type 1 assembly, release, and maturation. , 2007, Advances in pharmacology.
[4] Erez Pery,et al. Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type 1 Vif and Inhibitors of Vif-APOBEC3G Binding , 2007, Journal of Virology.
[5] David E. Martin,et al. Determinants of activity of the HIV-1 maturation inhibitor PA-457. , 2006, Virology.
[6] D. Trono,et al. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis , 1995, Journal of virology.
[7] Pierre Boulanger,et al. The 3-O-(3’,3’-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells , 2007, Antiviral therapy.
[8] M. Hammarskjöld,et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines , 1997, Journal of virology.
[9] B. Carlson,et al. Association of Human Immunodeficiency Virus Type 1 Vif with RNA and Its Role in Reverse Transcription , 2000, Journal of Virology.
[10] S. S. Hong,et al. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells , 1992, Journal of virology.
[11] B. Strack,et al. Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.
[12] K. Ravichandran,et al. Human Immunodeficiency Virus Type 1 Nef Associates with Lipid Rafts To Downmodulate Cell Surface CD4 and Class I Major Histocompatibility Complex Expression and To Increase Viral Infectivity , 2004, Journal of Virology.
[13] E. Freed,et al. The cell biology of HIV-1 and other retroviruses , 2006, Retrovirology.
[14] K. Sano,et al. Anti-Human Immunodeficiency Virus Activity of YK-FH312 (a Betulinic Acid Derivative), a Novel Compound Blocking Viral Maturation , 2001, Antimicrobial Agents and Chemotherapy.
[15] J. Mouscadet,et al. The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[16] B. Gay,et al. Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles , 1995, Journal of virology.
[17] É. Cohen,et al. Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae , 2004, Retrovirology.
[18] C. Jones,et al. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41 , 1997, Journal of virology.
[19] P. Sova,et al. Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity , 1994, Journal of virology.
[20] L. Selig,et al. HEED, the Product of the Human Homolog of the Murineeed Gene, Binds to the Matrix Protein of HIV-1* , 1999, The Journal of Biological Chemistry.
[21] R. Gorelick,et al. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles , 1995, Journal of virology.
[22] C. Tian,et al. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. , 2006, Virology.
[23] Morris S. Jones,et al. A Conserved Dileucine-Containing Motif in p6gag Governs the Particle Association of Vpx and Vpr of Simian Immunodeficiency Viruses SIVmac and SIVagm , 1999, Journal of Virology.
[24] E. Freed,et al. HIV-1 gag proteins: diverse functions in the virus life cycle. , 1998, Virology.
[25] U. Schubert,et al. Human Immunodeficiency Virus Type 1 Vpr Protein Is Incorporated into the Virion in Significantly Smaller Amounts than Gag and Is Phosphorylated in Infected Cells , 2000, Journal of Virology.
[26] C. Aiken,et al. Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation , 2004, Journal of Virology.
[27] A. Friedler,et al. Human immunodeficiency virus type 1 Vif‐derived peptides inhibit the viral protease and arrest virus production , 1998, FEBS letters.
[28] M. Resh,et al. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids , 1994, Journal of virology.
[29] C. Aiken,et al. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid , 2004, Retrovirology.
[30] P Boulanger,et al. Morphopoietic determinants of HIV-1 Gag particles assembled in baculovirus-infected cells. , 1998, Virology.
[31] E. Decroly,et al. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. , 2001, The Journal of general virology.
[32] E. Freed,et al. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions , 1996, Journal of virology.
[33] B. Spire,et al. Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. , 1998, The Journal of general virology.
[34] H. Kalbitzer,et al. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. , 1996, Virology.
[35] F. Kirchhoff,et al. Proline 35 of Human Immunodeficiency Virus Type 1 (HIV-1) Vpr Regulates the Integrity of the N-Terminal Helix and the Incorporation of Vpr into Virus Particles and Supports the Replication of R5-Tropic HIV-1 in Human Lymphoid Tissue Ex Vivo , 2007, Journal of Virology.
[36] E. Stephens,et al. Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal. , 2001, AIDS research and human retroviruses.
[37] E. Freed,et al. Retrovirus budding. , 2004, Virus research.
[38] E. Decroly,et al. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles. , 2005, Biochemical and biophysical research communications.
[39] Curtis McMurtrey,et al. 3-O-(3′,3′-Dimethysuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency Virus Type 1 Gag Precursor Assembled In Vitro , 2006, Journal of Virology.
[40] R. Murali,et al. Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[41] E. Freed,et al. Genetic Evidence for an Interaction between Human Immunodeficiency Virus Type 1 Matrix and α-Helix 2 of the gp41 Cytoplasmic Tail , 2000, Journal of Virology.
[42] Xianghui Yu,et al. Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. , 2007, Organic & biomolecular chemistry.
[43] J. Kappes,et al. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures , 1995, Journal of virology.
[44] S. Höglund,et al. A Putative α-Helical Structure Which Overlaps the Capsid-p2 Boundary in the Human Immunodeficiency Virus Type 1 Gag Precursor Is Crucial for Viral Particle Assembly , 1998, Journal of Virology.
[45] M. Malim,et al. Mutational Analysis of the Human Immunodeficiency Virus Type 1 Vif Protein , 1999, Journal of Virology.
[46] A. Rein,et al. RNA is a structural element in retrovirus particles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Resh. Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles. , 2005, AIDS reviews.
[48] M. Khan,et al. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. , 2003 .
[49] A. Kaplan,et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.
[50] L. Selig,et al. Interaction with the p6 Domain of the Gag Precursor Mediates Incorporation into Virions of Vpr and Vpx Proteins from Primate Lentiviruses , 1999, Journal of Virology.
[51] D. Gabuzda,et al. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains , 1995, Journal of virology.
[52] C. Labranche,et al. Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. , 2004, Virology.
[53] C. Dauguet,et al. Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity , 1995, Journal of virology.
[54] Wesley I. Sundquist,et al. Biochemical Analyses of the Interactions between Human Immunodeficiency Virus Type 1 Vpr and p6Gag , 2001, Journal of Virology.
[55] J. Cunningham,et al. Visualization of Retroviral Replication in Living Cells Reveals Budding into Multivesicular Bodies , 2003, Traffic.
[56] C. Aiken,et al. Inhibition of HIV-1 Maturation via Drug Association with the Viral Gag Protein in Immature HIV-1 Particles* , 2005, Journal of Biological Chemistry.
[57] B. Gay,et al. Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells , 1994, Journal of virology.
[58] David E. Martin,et al. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[59] R. Murali,et al. Functional Role of Residues Corresponding to Helical Domain II (Amino Acids 35 to 46) of Human Immunodeficiency Virus Type 1 Vpr , 2000, Journal of Virology.
[60] C. Aiken,et al. Betulinic acid derivatives as HIV-1 antivirals. , 2005, Trends in molecular medicine.
[61] H. Kräusslich,et al. Virion Incorporation of Human Immunodeficiency Virus Type 1 Nef Is Mediated by a Bipartite Membrane-Targeting Signal: Analysis of Its Role in Enhancement of Viral Infectivity , 1998, Journal of Virology.
[62] M. Foti,et al. HIV‐1 Egress is Gated Through Late Endosomal Membranes , 2003, Traffic.
[63] C. Aiken,et al. Disassembly of Human Immunodeficiency Virus Type 1 Cores In Vitro Reveals Association of Nef with the Subviral Ribonucleoprotein Complex , 2003, Journal of Virology.
[64] Kunio Nagashima,et al. In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat) , 2006, Journal of Virology.
[65] K. Strebel,et al. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein , 1996, Journal of virology.
[66] B. Roques,et al. NMR structure of the HIV-1 regulatory protein VPR. , 2003, Journal of molecular biology.
[67] E. Freed,et al. Cell-Type-Dependent Targeting of Human Immunodeficiency Virus Type 1 Assembly to the Plasma Membrane and the Multivesicular Body , 2004, Journal of Virology.
[68] S. Pettit,et al. Proteolytic Processing of the P2/Nucleocapsid Cleavage Site Is Critical for Human Immunodeficiency Virus Type 1 RNA Dimer Maturation , 2001, Journal of Virology.
[69] B. Spire,et al. Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor , 1997, Journal of virology.
[70] É. Cohen,et al. Incorporation of Vpr into Human Immunodeficiency Virus Type 1 Requires a Direct Interaction with the p6 Domain of the p55 Gag Precursor* , 1999, The Journal of Biological Chemistry.
[71] J. Goncalves,et al. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. , 2004, Genes & development.
[72] M. Khan,et al. High Level Expression of Human Immunodeficiency Virus Type-1 Vif Inhibits Viral Infectivity by Modulating Proteolytic Processing of the Gag Precursor at the p2/Nucleocapsid Processing Site* , 2004, Journal of Biological Chemistry.
[73] Y. Xiong,et al. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. , 2007, Journal of molecular biology.
[74] S. S. Hong,et al. Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. , 1991, Virology.